Novo Nordisk, Eli Lilly shares drop as Trump vows weight-loss drug price cuts
NegativeFinancial Markets

Shares of Novo Nordisk and Eli Lilly have taken a hit following President Trump's announcement to cut prices on weight-loss drugs. This move could significantly impact the profitability of these companies, which have been leading the market in obesity treatments. Investors are concerned about how these price cuts will affect sales and revenue, making it a crucial moment for the pharmaceutical industry.
— Curated by the World Pulse Now AI Editorial System